Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 18Lymphoma 12Lymphoma, Non-Hodgkin 11Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, B-Cell, Marginal Zone 5Leukemia, Hairy Cell 4Burkitt Lymphoma 4Recurrence 3Neoplasms 3Lymphoma, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Infections 2Epstein-Barr Virus Infections 2beta-Thalassemia 1Thalassemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphatic Diseases 1Lymphadenopathy 1Leukemia, Prolymphocytic 1

Interventions

obinutuzumab 1acalabrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × Rituximab × 30 days × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡